Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Deferoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | KDM4A | O75164 | 8/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.92 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.92 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.92 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferoxamine SCHEMBL119982 | 1.00 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL7715593 | 1.00 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL30036991 | 1.00 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL3953046 | 0.99 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9351925 | 0.99 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL2165915 | 0.97 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1034134 | 0.97 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9555338 | 0.96 | KDM4E (0.93) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL34571 | 0.96 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL21051754 | 0.96 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104342383-B | A kind of bacterial strain LD 11 that can promote plant growth under drought stress and its application | 广西大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20160136237-A1 | NGAL AND URINARY TRACT INFECTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-19 | — | — | US | disclosed |
| CN-104342383-A | Strain LD-11 capable of promoting growth of plant under condition of drought stress and application of strain LD-11 | UNIV GUANGXI | 2015-02-11 | — | — | CN | disclosed |
| US-20130157932-A1 | NGAL AND URINARY TRACT INFECTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011140554-A1 | NGAL AND URINARY TRACT INFECTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20070087047-A1 | Enhanced circulation effector composition and method | ALZA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-7160554-B2 | Enhanced circulation effector composition and method | ALZA CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7150882-B2 | Enhanced circulation effector composition and method | ALZA CORPORATION (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2005069750-A2 | THERAPEUTIC COMPOSITION WITH NANOSCALE ACTIVATION AGENTS | HEMOLYTICS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20040247663-A1 | Liposomes with effector biomolecules attached to the distal ends of hydrophilic polymer chains provide increased time in the bloodstream; polymyxin B used for septic shock | ALZA CORPORATION | 2004-12-09 | — | — | US | disclosed |
| EP-0496835-A1 | SOLID TUMOR TREATMENT METHOD AND COMPOSITION. | LIPOSOME TECHNOLOGY INC (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5084160-A | Method for solubilization of low-rank coal using low molecular weight cell-free filtrates derived from cultures of coriolus versicolor | ELECTRIC POWER RESEARCH INSTITUTE, INC. | 1992-01-28 | — | — | US | disclosed |
| US-5013556-A | Lipids derivatized with polyoxyethylene glycol, drug delivery, antitumor agents | LIPOSOME TECHNOLOGY, INC. (US) | 1991-05-07 | — | — | US | disclosed |
| WO-1991005545-A1 | LIPOSOME MICRORESERVOIR COMPOSITION AND METHOD | LIPOSOME TECHNOLOGY, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
| WO-1991005546-A1 | SOLID TUMOR TREATMENT METHOD AND COMPOSITION | LIPOSOME TECHNOLOGY, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
| EP-0245433-A4 | MAJOR IRON-REGULATED PROTEIN OF NEISSERIA GONORRHOEAE AND ITS USE AS VACCINE. | OREGON STATE (US) | 1988-08-04 | — | — | EP | disclosed |
| EP-0245433-A1 | MAJOR IRON-REGULATED PROTEIN OF NEISSERIA GONORRHOEAE AND ITS USE AS VACCINE | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1987-11-19 | — | — | EP | disclosed |
| EP-0237189-A2 | Therapeutic and related uses of dithiol peptides | REPLIGEN CORPORATION (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4681761-A | CATIONIC SURFACTANTS, ION EXCHANGING, CHROMATOGRAPHY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1987-07-21 | — | — | US | disclosed |
| WO-1987002678-A1 | MAJOR IRON-REGULATED PROTEIN OF NEISSERIA GONORRHOEAE AND ITS USE AS VACCINE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON (US) | 1987-05-07 | — | — | WO | disclosed |